{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P19544",
      "entity_text" : "WT1",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "cellosaurus:CVCL_E031" ],
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0448" ],
      "CellType" : [ "cl:CL:0000084" ]
    }
  },
  "verbose_text" : "The trial included five male and five female patients, with a median age of 40 years (range, 28-49 years), who were categorized as high-risk AML mainly based on the higher expression levels of WT1 at initial diagnosis [XREF_BIBR, XREF_BIBR] and received an allogeneic sibling donor HSCT followed by anti-leukemic WT1-CTLs infusion.",
  "reading_complete" : "2020-08-05T21:46:48Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T21:45:11Z",
  "trigger" : "levels",
  "evidence" : [ "levels of WT1" ],
  "pmc_id" : "6760543",
  "score" : 0
}